Do you want to read an article? Please log in or register.
DREAMM-9: High efficacy of belamaf in combination with VRd across all dosing cohorts in transplant-ineligible NDMM
Multiple Myeloma (MM)
CHICAGO 2026
Related content
ASH 2025
Multiple Myeloma (MM)
BENEFIT: Isa-VRd achieves superior sustained MRD negativity in transplant-ineligible NDMM
EHA 2025
Multiple Myeloma (MM)
GMMG-CONCEPT: Isatuximab plus KRd leads to high and sustained MRD negativity in transplant-eligible patients with high-risk NDMM
Multiple Myeloma (MM)
Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis®)-Based Regimens in Patients with NDMM
Leukemia
Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia
Br J Haematol
Desai N, Althobaiti M, Chen C, Al-Shaibani E, Moya TA, Novitzky-Basso I, Pasic I, Michelis FV, Kim DD, Kumar R, Mattsson J, Law AD, Viswabandya A
doi: 10.1111/bjh.70380
Multiple Myeloma (MM)
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial
Blood
Lahuerta JJ, San-Miguel JF, Jiménez-Ubieto A, Alonso Fernández R, Paiva B, Puig N, Cedena MT, Gutierrez NC, Calasanz MJ, Fernandez M, Ríos-Tamayo R, Oriol A, Blanchard MJ, Carrillo-Cruz E, Martínez-Martínez R, Bargay J, Sureda A, de la Rubia J, Hernandez Garcia MT, Cabañas V, Casado Montero LF, Palomera Bernal L, Gonzalez-Montes Y, Martínez-López J, Rodriguez-Otero P, Krsnik I, Arguiñano JM, Gonzalez-Garcia ME, Ocio EM, de la Cruz J, Mateos MV, Rosiñol L, Bladé J
doi: 10.1182/blood.2025028313
Lymphoma
Late infections after high-dose therapy and autologous stem cell transplantation for lymphoma: A Danish population-based study
Br J Haematol
Severinsen FT, Simonsen MR, Futtrup Maksten E, Jakobsen LH, Jensen RK, Søgaard KK, Jensen P, Brown PN, Mészáros Jørgensen J, Larsen TS, Poulsen CB, El-Galaly TC
doi: 10.1111/bjh.20262
Lung, Respiratory and Thoracic Cancer
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort
J Thorac Oncol
Illini O, Hund AC, Kopp HG, Moskovitz M, Mountzios G, Brueckl WM, Früh M, Leßmann ME, Christopoulos P, Stenzinger A, Thomas M, Gillis R, Peled N, Acker F, Addeo A, Charpidou A, Grohé C, Mauti L, Rothschild SI, Schmid S, Schumann C, Urban D, Wurm R, Ekman S, Skribek M, Glanemann F, Wiesweg M, Ackermann CJ, Agelaki S, Hoffknecht P, Jakopović M, Kern J, König D, Kostenzer K, Kropf-Sanchen C, Laack E, Lang D, Nagl L, Pall G, Reck M, Kian W, Allemann AT, Alt J, Araújo D, Bokas A, Hannah F, Julie KJ, Weinlinger C, de Langen AJ, Fergadis EG, Fountzilas E, Froesch P, Frost N, Griesinger F, Jordan F, Karanikiotis C, Kiesewetter B, Korantzis I, Machado AL, Economopoulou P, Pilz A, Reimann P, Rittmeyer A, Saad A, Samitas K, Schulmann K, Shah R, Stratmann JA, Taghizadeh H, Tammoscheit K, Tufman A, Weber JP, Wöll E, Valipour A, Overbeck TR, Hochmair MJ
doi: 10.1016/j.jtho.2026.103651
Genitourinary Cancer
Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study
Eur J Cancer
Ong M, Suzuki H, Smith M, Tombal B, Hussain M, Saad F, Fizazi K, Verholen F, Pham H, Srinivasan S, Lalani AA
doi: 10.1016/j.ejca.2026.116264
COMMENTED
Genitourinary Cancer
Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Eur Urol
Scilipoti P, Zaurito P, Longoni M, Colecchia M, Montorsi F, Salonia A, Mercinelli C, Maiorano B, Necchi A, Briganti A, Moschini M
doi: 10.1016/j.eururo.2025.12.022